ACTOS

Found in: Austria Australia Spain Hong Kong Lithuania Netherlands Singapore United Kingdom United States

Active ingredients

#
Active Ingredient
Description
1

Pioglitazone effects may be mediated by a reduction of insulin resistance. Pioglitazone appears to act via activation of specific nuclear receptors (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells in animals. Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance.

Medicine classification

ATC Code
Title
Class
Pioglitazone
A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BG Thiazolidinediones

Product monographs

Monograph
Type
Country
MPI, US: SPL/PLR
US

Identifiers

Authority
Identifier(s)
FDA, National Drug Code (US)
Identifier(s): 64764-151, 64764-301, 64764-451
Health Sciences Authority (SG)
Identifier(s): 12441P, 12442P
Pharmaceutical Benefits Scheme (AU)
Identifier(s): 8694N, 8695P, 8696Q
Z-Index G-Standaard PRK (NL)
Identifier(s): 84247, 84255
Centro de información online de medicamentos de la AEMPS (ES)
Identifier(s): 00150001, 00150004, 00150004IP, 00150009, 00150010, 00150010IP
Medicines & Healthcare Products Regulatory Agency (GB)
Identifier(s): 140403, 140405, 161338, 175725, 175728, 178953, 180500, 198640, 20095, 20096, 374281, 374283, 374285, 51997
Valstybinė vaistų kontrolės tarnyba (LT)
Identifier(s): 1004071, 1004363, 1004508, 1026399, 1026400, 1026401, 1026402, 1026403, 1026404, 1026405, 1026406, 1026407, 1026408, 1026409, 1026410, 1026411, 1026412, 1026413, 1026414, 1026415, 1026416, 1026417, 1026418, 1026419, 1063617, 1063618, 1063619, 1063620, 1063621, 1063622
Department of Health Drug Office (HK)
Identifier(s): 47882, 47884